Core Points - Embecta Corp. announced the resignation of David J. Albritton from the Board of Directors due to personal reasons, effective immediately [1] - LTG (Ret.) David F. Melcher will not seek re-election at the 2026 annual stockholder meeting and will retire from the Board due to other commitments [1] - Both Albritton and Melcher have been Directors since the Board's inception in 2022 [1] Leadership Transition - Devdatt "Dev" Kurdikar, President and CEO, expressed gratitude for the contributions of both departing Directors, highlighting their leadership during the company's establishment [2] - Kurdikar noted the importance of Melcher's mentorship and leadership in navigating complex initiatives [2] - The Board plans to appoint Kurdikar as Chairman and Dr. Claire Pomeroy as Lead Independent Director upon Melcher's departure [2] Company Overview - Embecta is transitioning from its initial phase to a focus on growth, with a commitment to prioritize the needs of customers, employees, and shareholders [2] - The company has a 100-year legacy in insulin delivery and aims to become a broad-based medical supplies company [3] - Embecta employs approximately 2,000 individuals globally, dedicated to improving lives through innovative solutions [3]

Core Insights - The eosera® Foundation Pitch Competition awarded Cherie Turner, CEO and Founder of Mommy Scrubs, a total of $35,000, including a $30,000 first place award and a $5,000 people's choice award, highlighting the support for women entrepreneurs in the healthcare sector [2][3][9]. Company Highlights - Mommy Scrubs, founded by Cherie Turner, focuses on designing postpartum scrubs specifically for breastfeeding mothers in healthcare, addressing the challenges faced by these professionals [7][8]. - The company has developed a patent-pending design that allows for easy pumping access while maintaining the functionality of standard scrubs, indicating a strong market need and innovative approach [8]. Industry Context - The competition, hosted by the eosera® Foundation, received over 250 applications, showcasing the growing interest and participation of women entrepreneurs in the business landscape [3][4]. - Fort Worth is recognized as the second fastest-growing area for women-owned businesses in the U.S., reflecting a positive trend in female entrepreneurship [4]. - The event emphasized the importance of supporting small businesses and entrepreneurs as a foundation for economic growth, aligning with broader trends in investment and community support for women-led initiatives [5][12].

Nov 14, 2025 3:13 PM Eastern Standard Time Retractable Technologies, Inc. Results for the Periods Ended September 30, 2025 Share LITTLE ELM, Texas--(BUSINESS WIRE)--Retractable Technologies, Inc. (NYSE American: RVP) reports total net sales of $10.1 million for the third quarter of 2025 and an operating loss of $3.7 million for the period, as compared to total net sales for the same period last year of $10.3 million and an operating loss of $5.1 million. For the first nine months of the year, net sales were ...

Nov 14, 2025 2:49 PM Eastern Standard Time Retractable Technologies, Inc. Receives Innovative Technology Designation from Vizient for EasyPoint Blood Collection Tube Holder with Needle Share LITTLE ELM, Texas--(BUSINESS WIRE)--Retractable Technologies, Inc. (NYSE American: RVP) announces its EasyPoint® Blood Collection Tube Holder with Needle has received an Innovative Technology designation from Vizient, the largest healthcare performance improvement company in the country. Each year, healthcare experts se ...

Core Insights - embecta Corp. has expanded its partnership with Direct Relief to enhance access to diabetes care for underserved communities in the U.S. and globally [1][2][3] Company Overview - embecta was spun off from Becton, Dickinson and Company in 2022, acquiring BD-branded pen needles and insulin syringes [2] - The company has updated its packaging in North America from the BD brand to the embecta brand in 2025 [2] - Since becoming independent, embecta has focused on empowering individuals with diabetes and ensuring access to necessary supplies [3] Partnership Details - embecta has donated approximately 15 million units of pen needles and insulin syringes to Direct Relief, marking its largest humanitarian partnership since independence [2] - The partnership aims to provide essential diabetes management supplies to uninsured and low-income patients through Direct Relief's Safety Net Support Program [4][5] - Direct Relief collaborates with over 1,600 community health centers and clinics, serving more than 36 million patients, including a significant portion of the uninsured population in the U.S. [4] Global Impact - The partnership supports Direct Relief's Life for a Child program, which provides diabetes care to over 53,000 children and young people in 45 countries [6] - embecta's donations also support diabetes care in crisis-affected regions, including a recent donation of 2.7 million insulin needles and syringes for a campaign in Sudan [8][7] Educational Initiatives - embecta supports diabetes education camps through Direct Relief, providing essential supplies to help children and young adults learn diabetes management skills [10] Emergency Response - The partnership includes emergency response capabilities, with a recent grant of $25,000 from embecta to support disaster relief efforts in Texas [11] Industry Context - Over 537 million people globally live with diabetes, with projections reaching 783 million by 2045; in the U.S., approximately 38 million individuals are affected [12] - Access to affordable diabetes care remains a critical challenge, particularly for uninsured and underinsured populations [12]

Financial Data and Key Metrics Changes - Net sales for Q3 2025 were $15.9 million, reflecting a 44% decrease from $28.3 million in Q3 2024, primarily due to the transition of the largest customer to another supplier [14] - Gross profit for Q3 2025 was $2.3 million, a 64% decrease from $6.2 million in Q3 2024, with a gross margin of 14%, down from 22% in Q3 2024 [14][15] - Adjusted EBITDA for Q3 2025 was $50,000, an improvement from negative $200,000 in Q2 2025 and negative $400,000 in Q1 2025 [16] - Cash and cash equivalents increased to $23.7 million from $18.4 million at the end of Q2 2025, driven by the issuance of common stock [16][17] Business Line Data and Key Metrics Changes - The company signed several new long-term product purchasing agreements, including a notable three-year commitment with a dialysis center in Southern Florida, potentially generating approximately $1 million in annualized net sales [8] - Expanded product purchase agreement with the largest provider of dialysis in skilled nursing facilities in the U.S., effective for three years [9] Market Data and Key Metrics Changes - The largest customer represented 12% of net sales in Q3 2025, indicating reduced dependence on any single customer due to successful diversification efforts [10] - The company is actively pursuing business development opportunities across various customer segments and geographic markets, reinforcing optimism about growth in 2026 and beyond [8] Company Strategy and Development Direction - The company is focused on right-sizing its organization to enhance operational efficiency while maintaining high-quality customer service [4][5] - Strategic decisions made earlier in the year are translating into tangible results, with over 80% of customers operating under long-term agreements, providing stability and revenue visibility [4][6] - The introduction of a new bicarbonate cartridge is expected to significantly grow the higher-margin product opportunity [25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving full-year guidance targets and sustainable profitability moving forward [6][7] - The transition period with the largest customer is expected to resolve within the current quarter, with ongoing discussions regarding future commitments [21][24] - The company anticipates providing forward revenue guidance for 2026 early in the year, with plans for potential acquisitions to enhance growth [22][24] Other Important Information - The company is actively restructuring its operations to align with changes in the customer base, focusing on improving efficiency and reducing costs [12][30] - A facility closure was executed to consolidate manufacturing activities, which is expected to reduce operating expenses [32] Q&A Session Summary Question: When will the situation with the former largest customer be resolved? - Management expects resolution within the current quarter and is in contract discussions [21] Question: When will forward revenue guidance for 2026 be provided? - Guidance is typically provided early in the year, with visibility expected during the fourth quarter earnings release [24] Question: What are the key prospects for the bicarbonate disposables business? - The introduction of the bicarbonate cartridge is expected to significantly grow this higher-margin product opportunity [25] Question: How is the company balancing organizational restructuring with investments? - The company is reallocating resources to focus on growth opportunities while winding down unsupported operations [28] Question: Where is there room for improving gross margin? - Immediate focus is on labor costs, with long-term potential in reducing materials and distribution costs [30][31] Question: Update on West Coast expansion and home dialysis business? - The West Coast is seen as a growth area, with potential announcements on new customers expected soon; home dialysis remains a small but growing segment [38][40][41]

Financial Data and Key Metrics Changes - Net sales for Q3 2025 were $15.9 million, reflecting a 44% decrease from $28.3 million in Q3 2024, primarily due to the transition of the largest customer to another supplier [14] - Gross profit for Q3 2025 was $2.3 million, a 64% decrease from $6.2 million in Q3 2024 [14] - Adjusted EBITDA for Q3 2025 was $50,000, an improvement from negative $200,000 in Q2 2025 and negative $400,000 in Q1 2025 [16] - Cash and cash equivalents increased to $23.7 million from $18.4 million at the end of Q2 2025 [17] Business Line Data and Key Metrics Changes - The company reported a gross margin of 14% for Q3 2025, down from 22% in Q3 2024, but excluding restructuring costs, gross margin was 18%, showing improvement over the first two quarters of 2025 [15] - The transition of the largest customer represented 12% of net sales in Q3 2025, indicating reduced dependence on any single customer [10] Market Data and Key Metrics Changes - The company signed several new long-term product purchasing agreements during Q3 2025, including a notable three-year commitment with a dialysis center in Southern Florida, potentially generating approximately $1 million in annualized net sales [8] - Discussions with the formerly largest customer are ongoing, with expectations to continue supplying them through the end of the year [9] Company Strategy and Development Direction - The company is focused on optimizing its organizational structure to align with current scale while enhancing operational efficiency and customer service [5] - Strategic decisions made earlier in the year are translating into tangible results, with over 80% of customers operating under long-term agreements, providing stability and revenue visibility [4] - The company is actively pursuing business development opportunities, including potential acquisitions, leveraging its strong cash position [24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving full-year guidance targets and sustainable profitability moving forward [6] - The company anticipates providing forward revenue guidance for 2026 early in the year, with expectations to announce business development impacts shortly [24] Other Important Information - The company is expanding its customer base on the West Coast and is considering establishing a facility there due to growing customer demand [38] - The at-home dialysis market is seen as a significant growth opportunity, with expectations for continued growth in this segment [40] Q&A Session Summary Question: Resolution timeline with former largest customer - Management expects the situation to resolve within the current quarter and is in contract discussions [21] Question: Forward revenue guidance for 2026 - Guidance is typically provided early in the year, with visibility expected during the fourth quarter earnings release [24] Question: Key prospects for bicarbonate disposables business - The introduction of the bicarbonate cartridge is expected to significantly grow this higher margin product opportunity [25] Question: Balancing organizational restructuring with investments - The company is managing resource allocation carefully to focus on growth opportunities while winding down unsupported operations [28] Question: Areas for improving gross margin - Immediate focus is on labor costs, with long-term potential in materials and distribution efficiencies [30] Question: Background on facility closure - A facility was closed as part of consolidation efforts, with expenses being offloaded [32] Question: Update on West Coast expansion and home dialysis business - The West Coast is a focus area for customer acquisition, and the at-home market is expected to grow significantly [38][40]

Core Points - Embecta Corp. is transitioning from a company focused solely on insulin delivery to a broader medical supplies company, leveraging its 100-year legacy in the industry [1][3] - The company will host a conference call on November 25, 2025, at 8:00 a.m. ET to discuss its fiscal fourth quarter and full year 2025 financial results, along with preliminary financial guidance for fiscal year 2026 [1][2] Company Overview - Embecta employs approximately 2,000 employees globally and aims to improve lives through innovative solutions and partnerships [3] - The company is committed to advancing its legacy in insulin delivery while expanding its product offerings in the medical supplies sector [3]

Core View - United-Guardian, Inc. has experienced a significant decline in both sales and net income for the third quarter of 2025, with net sales falling 26% year-over-year to $2.26 million and net income dropping to $268,441, reflecting a challenging market environment [2][4]. Financial Performance - For Q3 2025, net sales decreased by 26% to $2.26 million from $3.06 million in Q3 2024, while net income fell to $268,441 from $865,484, resulting in a 68% drop in earnings per share to 6 cents from 19 cents [2]. - For the first nine months of 2025, net sales declined 22% to $7.58 million from $9.71 million, and net income decreased to $1.46 million from $2.75 million, with earnings per share down about 47% to 32 cents from 60 cents [2]. Revenue Mix & Key Metrics - The decline in sales was primarily driven by weakness in the cosmetic ingredients business, while sales of pharmaceutical products and medical lubricants increased by 10% and 6%, respectively, over the first nine months of 2025 compared to the same period in 2024 [3]. Market Challenges - The softness in the cosmetic segment is attributed to reduced purchases by Ashland Specialty Ingredients (ASI), the company's largest marketing partner, which has faced tariff and geopolitical challenges in Asia, leading to a shift towards lower-priced local suppliers [4]. - ASI's efforts to manage excess inventory have resulted in decreased orders from United-Guardian, negatively impacting overall sales [4]. Operational Performance - Income from operations fell to $215,072 in Q3 2025 from $949,128 a year earlier, and for the nine months, it decreased to $1.52 million from $3.09 million in 2024 [5]. - Other income sources, including investment income and gains on marketable securities, also declined year-over-year, further dampening overall financial results [5]. Management Insights & Strategic Initiatives - Management remains optimistic about the underlying strength in pharmaceutical and medical businesses, with plans to regain market share through competitive pricing strategies [6]. - Key growth initiatives include focusing on Renacidin, with efforts to secure placement on additional drug formularies to significantly increase sales [7]. - The company has entered a strategic distribution arrangement to expand its sexual wellness and personal care portfolio, aiming to diversify revenue sources and broaden geographic reach [8]. Profitability Factors - Profitability was pressured by an increase in the cost of sales as a percentage of net sales, reflecting product-mix shifts and a challenging pricing environment, particularly in the cosmetic ingredients segment [9]. - Operating expenses rose due to higher professional fees and increased research and development spending, which, while supporting long-term growth, added to near-term earnings pressure [10][11]. Outlook - Although United-Guardian did not provide numerical guidance for the remainder of 2025, management expressed a cautiously optimistic outlook, relying on ASI's efforts to restore competitiveness and distribution expansions to stabilize cosmetic ingredient sales [13]. - The current earnings weakness is viewed as driven more by external demand and inventory dynamics rather than a decline in the company's product portfolio [14]. Shareholder Returns - The company has continued its practice of returning cash to shareholders through dividends, declaring and paying out cash dividends during the first nine months of 2025, including a 35 cents per share dividend earlier in the year [15].

Core Viewpoint - InfuSystem Holdings, Inc. will participate in the 16th Annual Craig-Hallum Alpha Select Conference on November 18, 2025, showcasing its role as a leading national healthcare service provider [1][11]. Company Overview - InfuSystem Holdings, Inc. operates as a national healthcare service provider, facilitating outpatient care for durable medical equipment manufacturers and healthcare providers [3]. - The company utilizes a two-platform model: - **Patient Services**: This segment includes Oncology, Pain Management, and Wound Therapy, focusing on the last-mile solution for clinic-to-home healthcare [3]. - **Device Solutions**: This segment supports Patient Services and includes direct payer rentals, pump and consumable sales, and biomedical services and repair [3]. - InfuSystem is headquartered in Rochester Hills, Michigan, and operates Centers of Excellence in multiple states and Ontario, Canada [3]. Conference Participation - Carrie Lachance, President and CEO, and Barry Steele, CFO, will represent InfuSystem at the conference, which will be held at the Sheraton New York Times Square Hotel [1][2]. - The company will host in-person one-on-one meetings throughout the day for interested investors [2].